Latest Content

Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.

Public health professional Shambrekia Wise and her daughter Sandy discuss the origins of their travel-themed book series and its relevance to clinicians treating diverse young patients.

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Review the developments in GLP-1s in 2026.

A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.

New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.

ACP outlines ethical AI use in medicine—protect patient trust, curb bias, prevent deskilling, and guide transparent, equitable care.

Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.

International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.

Check out our pipeline updates from August!

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Neurobiology of antisocial behavior links prenatal stress, childhood trauma, toxins, and brain-circuit deficits to proactive vs reactive aggression and psychopathy.